Where to draw the line?

In line with RTOG 0815, this meta-analysis of over 10K patients enrolled in 11 randomized trials demonstrates—just like with breast cancer—there is no subset of prostate cancer that loses the relative advantage of androgen deprivation therapy (ADT) in addition to radiation, and it continues to have an impact the longer your give it. It’s up to you and your patient to decide if the absolute advantages are worth it. | Kishan, ASTRO 2021